Executive Summary
Key Points:
- HPS is defined by the triad: liver disease + intrapulmonary vascular dilatations (IPVDs) + impaired oxygenation
- Prevalence: 5–32% in liver transplant candidates depending on diagnostic criteria
- Hallmark diagnostic finding: CE-TTE showing delayed microbubble appearance in left atrium (>3 cardiac cycles)
- PaO2 <80 mmHg on room air or A-a gradient ≥15 mmHg establishes oxygenation criterion
- Liver transplantation is the only definitive treatment; no pharmacologic therapy is consistently effective
- HPS confers increased mortality and is an independent indication for MELD exception points
1. Clinical Relevance for Nephrologists
Hepatopulmonary syndrome represents a pulmonary vascular complication of liver disease that has direct implications for nephrologists managing patients with advanced cirrhosis. The overlap between HPS and hepatorenal syndrome (HRS) creates clinical scenarios requiring coordinated hepatology-nephrology-pulmonology care.
Nephrologists encounter HPS in several clinical contexts:
- Evaluation for simultaneous liver-kidney transplantation (SLKT)
- Management of dialysis patients with cirrhosis
- Perioperative care of liver transplant recipients who develop AKI
- Assessment of hypoxemia in hospitalized cirrhotic patients with concurrent kidney disease
2. Definition and Diagnostic Criteria
European Respiratory Society Task Force Criteria (2004)
HPS requires ALL three components:
- Liver disease (portal hypertension with or without cirrhosis)
- Intrapulmonary vascular dilatations (documented by CE-TTE or 99mTc-MAA scan)
- Impaired oxygenation: PaO2 <80 mmHg on room air OR A-a gradient ≥15 mmHg (≥20 mmHg if age >64)
Severity Classification
| Severity |
PaO2 (mmHg) |
A-a Gradient |
| Mild | ≥80 | ≥15 mmHg |
| Moderate | 60–79 | ≥15 mmHg |
| Severe | 50–59 | ≥15 mmHg |
| Very Severe | <50 | ≥15 mmHg |
3. Pathophysiology
Intrapulmonary Vascular Dilatations
The hallmark of HPS is dilatation of pulmonary precapillary and capillary vessels from the normal 8–15 μm to 15–500 μm diameter. This causes:
- Diffusion limitation: Oxygen cannot reach the center of dilated vessels
- Intrapulmonary right-to-left shunting: Blood passes through dilated vessels without adequate gas exchange
- Ventilation-perfusion mismatch: Preferential perfusion of dependent lung bases where IPVDs predominate
Molecular Mechanisms
- Increased hepatic production of endothelin-1 (ET-1) acts on pulmonary endothelial ETB receptors
- ETB receptor activation upregulates eNOS and iNOS
- Excess NO causes pulmonary vasodilation
- Carbon monoxide (CO) from heme oxygenase-1 contributes to vasodilation
- Bacterial translocation activates pulmonary macrophages via TNF-α
- VEGF drives angiogenesis creating arteriovenous communications
📚 Clinical Pearl — Orthodeoxia and Platypnea: Orthodeoxia is worsening hypoxemia in the upright position with improvement when supine. IPVDs predominate in lung bases; upright positioning increases perfusion to dilated vessels, worsening shunting. Platypnea (dyspnea worsened by upright position) accompanies orthodeoxia. These are near-pathognomonic for HPS.
4. Diagnosis
Contrast-Enhanced Transthoracic Echocardiography (CE-TTE)
Gold standard screening test: Agitated saline microbubbles (>10 μm) are normally trapped in pulmonary capillaries. In HPS, dilated vessels allow passage.
Positive result: Microbubbles in left atrium >3 cardiac cycles after right heart opacification. Sensitivity >95%.
99mTc-MAA Lung Perfusion Scan
Particles 20–50 μm normally trapped in pulmonary bed. Brain uptake >6% suggests significant shunting. Less sensitive than CE-TTE but quantifies shunt fraction.
Pulmonary Angiography
- Type 1: Diffuse vascular dilatation — NOT amenable to embolization
- Type 2: Discrete AV communications — potentially treatable with coil embolization
5. Management
Liver Transplantation — The Only Definitive Treatment
- Resolution in 80–85% within 6–12 months post-transplant
- PaO2 <50 mmHg: increased perioperative mortality (up to 30%)
- MELD exception points available for PaO2 <60 mmHg
⚠️ No Proven Pharmacologic Therapy: Inhaled NO, methylene blue, garlic, pentoxifylline, somatostatin, mycophenolate — none have been consistently effective. Liver transplantation remains the only definitive treatment.
6. Special Considerations for Nephrologists
HPS and Hepatorenal Syndrome
Both share splanchnic vasodilation as a common pathogenic mechanism. Combined HPS + HRS significantly complicates transplant candidacy and management.
SLKT Evaluation
Very severe HPS (PaO2 <50 mmHg) may contraindicate complex multi-organ transplantation due to prohibitive perioperative mortality risk.
Dialysis in HPS Patients
📚 Clinical Pearl: When dialyzing patients with HPS:
- Provide supplemental O2 during hemodialysis
- Recognize that volume shifts may worsen V/Q mismatch
- Expect increased hemodynamic instability risk
- Consider conservative ultrafiltration goals
References
- Rodríguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome. N Engl J Med. 2008;358(22):2378-2387. PubMed
- Krowka MJ, et al. International Liver Transplant Society practice guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension. Transplantation. 2016;100(7):1440-1452. PubMed
- Abrams GA, et al. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology. 1995;109(4):1283-1288. PubMed
- Schenk P, et al. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology. 2003;125(4):1042-1052. PubMed
- Rodríguez-Roisin R, et al. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J. 2004;24(5):861-880. PubMed
- Fallon MB, et al. Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome. Gastroenterology. 2008;135(4):1168-1175. PubMed
- Fallon MB. Mechanisms of pulmonary vascular complications of liver disease: hepatopulmonary syndrome. J Clin Gastroenterol. 2005;39(4 Suppl 2):S138-S142. PubMed
- Zhang J, Fallon MB. Hepatopulmonary syndrome: update on pathogenesis and clinical features. Nat Rev Gastroenterol Hepatol. 2012;9(9):539-549. PubMed
- Goldberg DS, et al. Hepatopulmonary syndrome: results from a multi-center prospective study. Gastroenterology. 2014;146(5):1256-1265. PubMed
- Iyer VN, et al. Hepatopulmonary syndrome: favorable outcomes in the MELD exception era. Hepatology. 2013;57(6):2427-2435. PubMed
- Angeli P, et al. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. PubMed
© Urine Nephrology Now — Clinical Mastery Series